CTOs on the Move

OvaScience

www.ovascience.com

 
OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ovascience.com
  • 215 First Street Suite 240
    Cambridge, MA USA 02142
  • Phone: 617.500.2802

Executives

Name Title Contact Details

Funding

OvaScience raised $82M on 06/02/2016

Similar Companies

HealthTell

HealthTell is committed to empowering the next generation of diagnostics and therapeutics for complex immune-mediated diseases such as cancer, autoimmune disorders, and infectious diseases. Based on robust proprietary technology, HealthTell is developing the first and only diagnostic platform capable of assessing an individual`s immune system response to specific diseases. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage health and make more informed decisions.

Uromedica

Uromedica, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Premiera Care Communities

Premiera Care Communities is a Oakdale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedXcel

MedXcel is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aileron Therapeutics

Aileron Therapeutics, based in Cambridge, Massachusetts, is a biopharmaceutical company developing and advancing a revolutionary class of drugs called Stapled Peptides. The company`s proprietary Stapled Peptides platform is a breakthrough approach to creating drugs for highly sought after biological targets using its novel peptide stabilizing technologies.